Somaxon Pharmaceuticals to Present Data at the 22nd Annual Meeting of the Associated Professional Sleep Societies

SAN DIEGO--(BUSINESS WIRE)--Jun 4, 2008 - Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced that one oral presentation and four posters, including data from the company's Phase 3 clinical trial program of its lead drug candidate SILENOR(TM) (doxepin HCl) for the treatment of insomnia, will be presented at the 22nd Annual Meeting of the Associated Professional Sleep Societies (APSS) in Baltimore, Maryland. The posters will be presented on Wednesday, June 11 (10:15 a.m. to 12:15 p.m. ET), and the oral presentation will be on Thursday, June 12 (8:00 a.m. to 8:15 a.m. ET). Data from these presentations are embargoed until they are presented.

In addition, Somaxon is sponsoring an educational symposium at the APSS meeting entitled, "Taking a Different Pathway: The Scientific Basis for the Unique Effects of Selective Antihistamines in the Treatment of Insomnia." This symposium will take place Monday, June 9 from 6:00 p.m. to 9:00 p.m. ET at the Sheraton Inner Harbor Hotel in Baltimore.

A summary of the Somaxon Pharmaceuticals APSS 2008 presentations is as follows:

-- APSS Oral Presentation # 0701; Long-term Efficacy and Safety of Doxepin 1 mg and 3 mg in Elderly Subjects with Chronic Primary Insomnia: A presentation of the results from a three-month Phase 3 clinical trial exploring the efficacy and safety of doxepin in elderly subjects with chronic primary insomnia.

-- APSS Poster Presentation # 0785; Consistency of Symptom Improvement in Elderly Subjects with Chronic Insomnia Treated with Doxepin 1, 3 and 6 mg: A presentation of the results from two Phase 3 clinical trials exploring the consistency of global symptom improvement measures in elderly subjects with primary insomnia treated with doxepin.

-- APSS Poster Presentation # 0784; Efficacy of Doxepin 3 and 6 mg on Early Awakenings in Adults with Primary Insomnia: A presentation of the effects of doxepin 3 mg and 6 mg on early morning awakening and next-day residual effects measures in a 35-day Phase 3 clinical trial in adults.

-- APSS Poster Presentation # 0783; Evaluation of Doxepin 3 and 6 mg in a 35-day Trial of Adults with Primary Insomnia Following Treatment Discontinuation: A presentation evaluating doxepin 3 and 6 mg following treatment discontinuation in a 35-day Phase 3 clinical trial of doxepin in adults.

-- APSS Poster Presentation # 0782; Efficacy and Safety of Doxepin 6 mg in a 4-week Outpatient Trial of Elderly Subjects with Primary Insomnia: A presentation of the results from a four-week Phase 3 outpatient clinical trial exploring the efficacy and safety of doxepin in elderly subjects with chronic primary insomnia.

About Somaxon Pharmaceuticals, Inc.

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon has completed four successful Phase 3 clinical trials for its lead product candidate, SILENOR(TM) (doxepin HCl) for the treatment of insomnia. The FDA recently notified Somaxon that it accepted the NDA for SILENOR(TM) for review as of March 31, 2008. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, Somaxon expects that the FDA will complete its review and provide an action letter to the company with respect to the NDA by December 1, 2008.

For more information, please visit the company's Web site at www.somaxon.com.

Contact

Investors:
Somaxon Pharmaceuticals, Inc.
Meg McGilley, Chief Financial Officer, 858-480-0402
or
PondelWilkinson, Inc.
Rob Whetstone, 310-279-5963
or
Media:
Manning, Selvage & Lee
Anne de Schweinitz, 212-468-3779

Posted: June 2008

View comments

Hide
(web1)